Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Rhythm Metabolic
AddedMar 20, 2024
UpdatedJun 18, 2026
Rhythm Metabolic

Rhythm Metabolic

Acquired

Developing genetic obesity treatment with setmelanotide. Subsidiary of Rhythm Pharmaceuticals. Established in 2013. HQ in Boston.

HQ
Boston, MA, US
Founded
2013
Overview
Compare
Fundraising
Employees

Rhythm Metabolic, established in 2013 and headquartered in Boston, Massachusetts, is a subsidiary of Rhythm Pharmaceuticals. The company focuses on developing treatments for genetic obesity, specifically through setmelanotide (RM-493), a novel peptide MC4 agonist targeting obesity caused by genetic deficiencies in the MC4 pathway.

Rhythm Metabolic has made significant strides in addressing rare genetic disorders linked to obesity. By advancing setmelanotide, the company has contributed to the development of targeted therapies, offering hope to patients with limited treatment options.

Rhythm Metabolic - Similar Companies

Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

rhythmtx.com

EndoMetabolic Solutions logo

EndoMetabolic Solutions

endometabolic.com

Energesis Pharmaceuticals logo

Energesis Pharmaceuticals

twenty30 health logo

twenty30 health

twenty30.health

Lobesity Investors logo

Lobesity Investors

MedRhythms logo

MedRhythms

Response Pharmaceuticals logo

Response Pharmaceuticals

Ammonett Pharma logo

Ammonett Pharma

Microbiome Therapeutics logo

Microbiome Therapeutics

Phenomix Sciences logo

Phenomix Sciences

ePurines logo

ePurines

Rheos Medicines logo

Rheos Medicines

Elcelyx Therapeutics logo

Elcelyx Therapeutics

RhythmScience logo

RhythmScience

GT Metabolic Solutions logo

GT Metabolic Solutions

gtmetabolic.com

Rhythm Metabolic - Quick Facts

Who are Rhythm Metabolic's competitors?

Companies similar to Rhythm Metabolic include Rhythm Pharmaceuticals, EndoMetabolic Solutions, Energesis Pharmaceuticals and twenty30 health.

When was Rhythm Metabolic founded?

Rhythm Metabolic was founded in 2013.

Where is Rhythm Metabolic's headquarters located?

Rhythm Metabolic's headquarters is located in Boston, MA, US.

When was Rhythm Metabolic's last funding round?

Rhythm Metabolic's most recent funding round was for $40M (USD) in August 2015.

How much has Rhythm Metabolic raised to-date?

As of Aug 13, 2015, Rhythm Metabolic has raised a total of $40M (USD).

Rhythm Metabolic - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Obesity Treatment
Tags
  • Healthtech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified